 |
| Convenient Oral Dosing |
- Recommended at 100 mg tid1
- May be taken with or without food1
- Patients with renal impairment require
reduced dose1
Recommendations for Patients With Renal
Impairment |
| The major
route of miglustat excretion is renal1;
therefore the following dose reductions are recommended: |
- Patients with mild renal impairment
(adjusted creatinine clearance 50–70 mL/min/1.73 m2)
start at 100 mg bid1
- Patients with moderate renal impairment
(adjusted creatinine clearance 30–50 mL/min/1.73 m2) start at 100 mg daily1
- Patients with severe renal impairment
(adjusted creatinine clearance <30 mL/min/1.73 m2) should
not receive Zavesca1
|
1. Zavesca® (miglustat)
package insert. Actelion
Ltd. 2003.
|
